De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study
Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Gabriella Moretti(Istituti di Ricovero e Cura a Carattere Scientifico), Tomás Pascual(Breast Cancer Research Foundation), Giancarlo Bisagni, Loredana Urso(Istituto Oncologico Veneto), Patricia Galván(Vall d'Hebron Institute of Oncology), Roberto Vicini, Enrico Orvieto(AULSS 2 Marca Trevigiana), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Maria Vittoria Dieci(Istituto Oncologico Veneto), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Aleix Prat(Hospital Clínic de Barcelona), Giulia Bianchi, M. Ambroggi(Guglielmo da Saliceto Hospital), Gian Luca De Salvo(Istituto Oncologico Veneto)
Cited by 97
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k